Form D — Gilgamesh Pharma Inc.
0002107396-26-000004 · filed Mar 31, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Pharmaceuticals filings
Offering
- Industry
- Pharmaceuticals
- Exemptions
- Rule 506(b)
- Reported offering amount
- $15,000,000
- Reported amount sold
- $2,250,000
- Minimum investment
- $50,000
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Gilgamesh Pharma Inc.
- CIK
- 2107396
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2025
- Address
- 113 UNIVERSITY PLACE, SUITE 1019
NEW YORK, New York 10003 - Phone
- 929-723-4861
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Jonathan Sporn · Executive OfficerNew York, New York Find on LinkedIn ↗
-
Andrew Kruegel · Executive OfficerNew York, New York Find on LinkedIn ↗
-
Amy Kruse · DirectorNew York, New York Find on LinkedIn ↗
-
Zia Huque · DirectorNew York, New York Find on LinkedIn ↗
-
Robert Berman · DirectorNew York, New York Find on LinkedIn ↗
-
Phil Skolnick · DirectorNew York, New York Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗